MSC2530818 is novel, potent, selective and orally available small molecule inhibitor of cyclin dependent kinase CDK8 with the IC50 of 2.6 nM.

Samuraciclib HCl (ICEC-0942; PPDA001; CT-7001), the hydrochloride salt of Samuraciclib, is a novel, potent, orally bioavailable and selective CDK7 inhibitor with potential anticancer activity.

BS-181 HCl (BS181; BS 181), the hydrochloride salt of BS181, is a novel, highly selective, and small molecule Cyclin-dependent kinase 7 (CDK7) inhibitor with potential antitumor activity.

Riviciclib (formerly P 276-00; P-27600; P276-00) is a flavonoid analog which acts as a potent inhibitor of CDK1 (cyclin-dependent kinase), CDK4 and CDK9 with potential antitumor activity. It inhibits CDK1/4/9 with IC50s of 79 nM, 63 nM and 20 nM, respectively.

RGB-286638 is a multi-targeted cyclin-dependent kinase (CDK) inhibitor.